Clinical Updates in Systemic Lupus ErythematosusImproved Diagnostic and Management Strategies
Crow MK. Arthritis Res Ther. 2009;11:245.
Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
Hochberg MC. Arthritis Rheum. 1997;40:1725.
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future
Jacob N, Stohl W. Autoimmunity. 2010;43:84-97.
Jacob N, Stohl W. Arthritis Res Ther. 2011;13:228.
Jordan N, et al. BMC Med. 2013;11:120.
Lateef A, Petri M. Arthritis Res Ther. 2012;14:S4.
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
Mosca M, et al. Ann Rheum Dis. 2010;69:1269-1274.
Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Parker B, et al. Ann Rheum Dis. 2013;72:1308-1314.
Petri M. Best Pract Res Clin Rheumatol. 2007;21:687-697.
Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between Belimumab and other inhibitors in development?
Stohl W. Curr Rheumatol Rep. 2012;14:303-309.
Tsokos GJ. N Engl J Med. 2011;365:2110-2121.
Scientific and Clinical Insights Into the Pathophysiology of Systemic Lupus Erythematosus
William Stohl, MD, PhD
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors